Clinical

Latest News

January 1st 2000

Celltrion Presents More Data Showing Comparable Efficacy, Safety of Subcutaneous CT-P13 to IV Form

Korean drug maker Celltrion Healthcare recently presented new findings from a 2-part study at the Annual European Congress of Rheumatology 2019 meeting about subcutaneous biosimilar CT-P13 (Inflectra, Remsima).

Latest Videos

Dr Yousuf Zafar Explains Interventions to Combat Rising Drug Prices

Dr Mark Fendrick Outlines His Preferred Outcomes For Medicare's VBID Demonstration

Dr Robert Green Explains Challenges, Promise of Big Data in Oncology

Judith Peres Discusses Misconceptions of Palliative Care

Dr Bruce Sherman Highlights Areas Where PBMs Can Help Employers

Dr Robert Dubois Highlights Expectations for Broader Clinical Pathway Adoption

Dr Joe V. Selby on Biosimilar Research

Dr Glen Stettin on Strategies for Managing High-Cost Treatments

Joy Larsen Haidle Discusses How Patients Should Use Genetic Tests

Dr Bruce Quinn Describes How Europe and the US Regulate Diagnostic Tests Differently

More News

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

How MCOs Should Be Preparing for the OBBBA's Medicaid Cuts: David Brueggeman, MBA

Early Data Show Revumenib Offers Maintenance Option in AML Following SCT